Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
You may also be interested in...
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.
Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.
The pool at the foot of the patent cliff is a dark, dynamic vortex. Teva's imminent acquisition of Allergan's generics division just about moves the needle: but it's big pharma that dominates the off-patent drugs business these days.